TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: In 2018, the FDA approved BV in combination with chemotherapy as front-line treatment for patients with CD30-expressing PTCL, based on the results of the pivotal ECHELON-2 trial.